Within the 2022 ELN AML diagnostic criteria, in the separate “AML with germline predisposition” category, it is highlighted that the BRCA1 and BRCA2 inherited mutations predispose not only to myeloid neoplasms but also to BC and ovarian cancers [14]. This evidence concerns the gene BRCA1 and myeloid neoplasm.